CYP 5.13% 20.5¢ cynata therapeutics limited

Ann: Cynata MSCs beneficial in preclinical ARDS study, page-10

  1. 270 Posts.
    lightbulb Created with Sketch. 264

    The COVID-19 front is a fast-moving beast!

    The sooner we announce something along the lines on, who “we are currently in discussions with <sic> about a possible clinical trial in human patients with ARDS, including those who have developed ARDS as a result of thedevastating COVID-19 pandemic” and when… the better!


    Imagine what an announcement this afternoon stating that a Large Pharma and Cynata have approval from the FDA to trial Cymerus MSCs on a number of NYC patients with ARDS would do…


    We can only wonder at this stage... if Ross is capable of any such thing!

    Last edited by mcnamm: 17/04/20
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
20.5¢
Change
0.010(5.13%)
Mkt cap ! $37.01M
Open High Low Value Volume
20.5¢ 20.5¢ 20.5¢ $480 2.343K

Buyers (Bids)

No. Vol. Price($)
2 15128 19.5¢
 

Sellers (Offers)

Price($) Vol. No.
20.5¢ 43657 1
View Market Depth
Last trade - 15.39pm 02/09/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.